Showing results (91-100 of 147) with videos related to

Sort By:
Pageof 15
Clinical & Experimental Ophthalmology|May 2, 2021
Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1-3 tyrosine kinase inhibitor anticancer therapyJason Charng, Mary S Attia, Sukanya Arunachalam, et al.
Scientific Reports|April 10, 2020
A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinomaBella Nguyen, Katie Meehan, Michelle R Pereira, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2020
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancerMarliese Alexander, Nick Pavlakis, Thomas John, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trialIan D Davis, Ben Brady, Richard F Kefford, et al.
Oncotarget|November 8, 2017
Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanomaAshleigh C McEvoy, Leslie Calapre, Michelle R Pereira, et al.
JCO Precision Oncology|September 11, 2020
Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal MelanomaAaron Beasley, Timothy Isaacs, Muhammad A Khattak, et al.
Histopathology|April 8, 2015
Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testingChristina Selinger, Wendy Cooper, Trina Lum, et al.
British Journal of Cancer|August 10, 2021
Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progressionGabriela Marsavela, Ashleigh C McEvoy, Michelle R Pereira, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samplesBoris Winterhoff, Luisa Freyer, Edward Hammond, et al.
Lung Cancer (Amsterdam, Netherlands)|January 6, 2020
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesotheliomaWei-Sen Lam, Jenette Creaney, Fred K Chen, et al.
Pageof 15